Data and Documentation
Open Data Policy
FAQ
EN
DE
FR
Suchbegriff
Advanced search
Publication
Back to overview
Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis
Type of publication
Peer-reviewed
Publikationsform
Original article (peer-reviewed)
Author
Grint Daniel, Peters Lars, Rockstroh Juergen K., de Wit Stephane, Mitsura Victor M., Knysz Brygida, Pedersen Court, Kirk Ole, Lundgren Jens D., Mocroft Amanda,
Project
Swiss HIV Cohort Study (SHCS)
Show all
Original article (peer-reviewed)
Journal
AIDS
Volume (Issue)
28(4)
Page(s)
577 - 587
Title of proceedings
AIDS
DOI
10.1097/qad.0000000000000069
Open Access
URL
http://doi.org/10.1097/QAD.0000000000000069
Type of Open Access
Publisher (Gold Open Access)
Abstract
Background: Most antiretroviral drugs are metabolized by the liver; hepatic disease or liver damage as a result of hepatitis C virus (HCV) could impair this metabolism leading to an increased risk of drug toxicity. This study aimed to determine the risk of antiretroviral drug discontinuation among HCV/HIV coinfected patients. Methods: EuroSIDA patients taking combination antiretroviral therapy were included. Poisson regression identified factors associated with antiretroviral treatment discontinuation. Results: A total of 9535 HIV-positive patients with known HCV status were included (6939 HCVAb-negative; 2596 HCVAb-positive at baseline). Viremic HCV infection was associated with a 44% increased risk of antiretroviral drug discontinuation compared with aviremic infection [adjusted incidence rate ratio, aIRR: 1.44 (95% confidence interval, CI 1.22–1.69)]; this relationship was largest among nonnucleoside reverse transcriptase inhibitors [aIRR: 1.59 (95% CI 1.18–2.14)]. In the subset of 935 HIV-positive patients also HCV-positive or HBV-positive with plasma hyaluronic acid measured, hyaluronic acid more than 100 ng/ml was associated with a 37% increased risk of antiretroviral drug discontinuation [aIRR: 1.37 (95% CI 1.08–1.73) vs. hyaluronic acid ≤100 ng/ml] and the effect of HCV viremia became nonsignificant; the largest drug association was seen for protease inhibitors [aIRR: 1.40 (95% CI 1.04–1.89)]. Conclusion: HCV viremia and high levels of hyaluronic acid predict antiretroviral drug discontinuation. Evidence was also found to suggest a link between impaired liver function and protease inhibitor toxicity.
-